Inactive Instrument

Asterias Biotherapeutics Inc Stock OTC Bulletin Board

US04624N1072

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- ^USD	-

Press Releases: Asterias Biotherapeutics Inc

19-01-24	Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury	GL
18-11-09	Asterias Biotherapeutics Reports Third Quarter Results	GL
18-11-08	Asterias Biotherapeutics : BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company	BU
18-11-08	Asterias Biotherapeutics : BioTime Reports Third Quarter 2018 Financial Results and Provides Business Update	BU
18-10-01	Asterias Biotherapeutics Announces Facilities and IP License Option Agreements	GL

More press releases

News in other languages: Asterias Biotherapeutics Inc

14-12-08

ThyssenKrupp : ECHO BONDS : Fitch relève la perspective de ThyssenKrupp à stable

More news

Managers and Directors: Asterias Biotherapeutics Inc

Manager	Title	Age	Since
Brian Culley CEO	Chief Executive Officer	54	2019-03-07
Jill Howe DFI	Director of Finance/CFO	50	-
George Samuel SEC	Corporate Secretary	45	-

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+0.59%	+2.73%	+1.48%	+28.74%	46.28B
IQVIA HOLDINGS INC.	+1.04%	+1.55%	+43.64%	+35.45%	43.85B
REVOLUTION MEDICINES, INC.	+1.00%	-6.05%	+333.91%	+532.22%	40.93B
BEONE MEDICINES AG	+4.18%	+3.07%	+7.96%	+94.21%	39.89B
CELLTRION, INC.	+1.11%	+1.80%	+11.52%	+43.15%	29.5B
MEDPACE HOLDINGS, INC.	+2.18%	+4.91%	+25.41%	+159.39%	17.09B
ASCENDIS PHARMA A/S	+1.05%	-9.67%	-	-	15.55B
EUROFINS SCIENTIFIC SE	+2.12%	+8.18%	+24.54%	+41.21%	15.22B
TEMPUS AI, INC.	+1.31%	+26.44%	-8.40%	-	14.05B
Average	+1.64%	+3.97%	+55.01%	+133.48%	29.15B
Weighted average by Cap.	+1.64%	+2.08%	+68.86%	+141.99%

See all sector performances

Asterias Biotherapeutics, Inc. is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients' immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient's own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells.

Employees

Sector

Biotechnology & Medical Research

More about the company